Flecainide

• UNSPSC Description:

  Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na+ current (INa) and the rapid component of the delayed rectifier K+ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias[1][2][3].

• Target Antigen:

  Potassium Channel; Sodium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/flecainide.html

• Purity:

  99.94

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C)

• Smiles:

  O=C(C1=CC(OCC(F)(F)F)=CC=C1OCC(F)(F)F)NCC2NCCCC2

• Molecular Weight:

  414.34

• References & Citations:

  [1]Echt DS, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8.|[2]Aliot E, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011 Feb;13(2):161-73.|[3]Allan LD, et al. Flecainide in the treatment of fetal tachycardias. Br Heart J. 1991 Jan;65(1):46-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  54143-55-4